类细胞膜仿生药物缓释涂层冠脉支架材料的研究  

Pilot Study of a Cell Membrane like Biomimetic Drug-eluting Coronary Stent

作　　者：范德增[1] 贾志远[1] 严心浩[1] 刘晓蕾[1] 董伟[1] 孙福玉[1] 计剑[2] 徐建平[2] 任科峰[2] 陈伟东[2] 沈家骢[2] 邱红[3] 高润霖[3] 

机构地区：[1]安泰科技股份有限公司,北京100081 [2]浙江大学高分子科学与工程学系,杭州310027 [3]阜外心血管病医院,北京100037

出　　处：《生物医学工程学杂志》2007年第3期599-602,共4页Journal of Biomedical Engineering

基　　金：国家高技术研究发展计划(863)资助项目"新型介入性治疗支架材料的研制"(2001AA326030)

摘　　要：由单体2-(甲基丙烯酰氧基)乙基-2-(三甲基氨基)乙基磷酸酯(MPC)、甲基丙烯酸十八酯(SMA)、甲基丙烯酸羟丙酯(HPMA)和甲基丙烯酸(三甲氧)硅基丙酯(TSMA)合成了一种新型类细胞膜涂层材料。接触角显示聚合物/水界面向更加亲水方向转化。这种类细胞膜能防止血小板黏附,显著延长复钙化时间。将雷帕霉素作为模型药物植被药物涂层支架,动物实验表明,这种涂层支架能有效预防再狭窄的发生。A novel bioinspired phospholipid copolymer has been synthesized by the radical polymerization of poly2-Methacryloyloxyethylphosphorylcholine （MPC）, stearyl methacrylate （SMA）, hydroxypropyl methacrylate （HPMA） and trimethoxysilylpropyl methacrylate （TSMA）. Contact angle results indicated that the coating surface rearranged to get a more hydrophilic surface at the polymer/water interface. The membrane mimic phosphorylcholine coating surface could resist the platelet adhesion and prolong plasma recalcification time significantly. Rapamycin was used as model drugs to prepare drug-eluting coating. The animal experiments showed that this novel drug-eluting stent could effectively prevent the phenomena of restenosis.

关 键 词：再狭窄 磷酸胆碱 仿生 药物缓释 

分 类 号：R318.08[医药卫生—生物医学工程]